Start Date: Monday, November 11, 2019
End Date: Friday, November 15, 2019
Event Category: Scientists
The 4th International Biomanufacturing Challenges of Immunotherapy Congress (BIOMIT 2019), to be held from November 11 to 15, 2019 in Varadero, Cuba is now an established congress, which attracts the intention of the participants to share, exchange and explore new trends and challenges of Biotechnology and Bioengineering and related research and the latest developments. The event will feature plenary speakers, established keynote speakers, active guest speakers and newly contributed speakers. In addition, a variety of poster presentations along with workshops and special sessions would be interested in the audience. We sincerely hope that BIOMIT 2019 will be an excellent opportunity to learn about Cuban Biotech's achievements, visit Cuban scientific centers, discuss, present new results, create new opportunities and new collaborative projects. More information on website
¡Stay informed of our latest news!
CIMAvax EGF ® is a therapeutic vaccine registered in Cuba (developed by the Center of Molecular Immunology (CIM), for advanced lung cancer. This therapeutic vaccine has a health history in the indication: Advanced non-small cell lung cancer (NSCLC) stage IIIb and IV, after the first line of chemotherapy. It is in this condition and type of lung cancer that the greatest clinical benefit is obtained in terms of increased survival and improved quality of life, as well as a broad safety profile in treated patients. This vaccine is not recommended for other types of cancer, apart from NSCLC, the tumor must be primary pulmonary, because we have no evidence of efficacy to date. It is necessary to know the histology and tumor stage of the patient, since CIMAvax EGF ® is only registered for non-small cell lung cancer of advanced stage IIIb and IV cells (NSCLC), in other types of tumors we have no evidence of clinical efficacy .
Questions of Interest:
Position of CIM for CIMAvax EGF®:
The Center for Molecular Immunology (CIM) is the center where it develops, produces and markets this medicine among other biotechnological products. This institution does not offer treatments to patients directly, nor does it inform about the price of the products they produce.
Foreign patients should contact the Cuban Medical Services who will evaluate each case if they are susceptible to treatment with these vaccines and receive it within a comprehensive program of patient care with commercial value.
You can contact them at these addresses:
At the International Clinic La Pradera:
Phones (537) 2737467 ext. 403
If you want a treatment outside of Cuba:
Laboratorio Libra Paraguay S.A
Dirección: Pedro Ciancio 1443 entre Santiago y San Cosme B Jara Asunción Persona de Contacto: Sr. Pablo Moreira Gerente Comercial
Correo electrónico: email@example.com
Teléfono: (595-21) 228 370
Móvil: (595) 986 679300
Sr. Alejandro Castaño.
Tel: + 57-4-334 40 33
Móvil: +57 - 311 301 8257
Cra.46 # 19 sur 117
Medellín, Colombia, América del Sur
Laboratorio Elea Phoenix S.A.
Sanabria 2353 (C1417AZE), Ciudad Autónoma de Buenos Aires, Argentina
Tel. (5411) 4379 4300 (int. 1266)
Director médico Dr. Matias DEPRATI
050033, Almaty, Khodzhanova street, 13 house, 69
CEO. Alina Ilimbayeva
+7 701 715 6000
Kraljice Natalije 46
Tel: +381 11 36 28 433
CEO. Mr. Zoran Vujovic.
Si necesita cualquier información adicional, no dude en contactarnos.